Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT00058370, this NA trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 12 times since 2003, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed NA
-
Jul 2019 — Jun 2020 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Mar 2019 — Jul 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting NA
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .